Government, Industry, Non-Profit, Academic Partners
Partnerships are the heart of our Wellstone MD CRC. Collaborators and expert consultants support the cores and projects are experts in their respective scientific, clinical and service areas.
The Wellstone MD CRC Biopsy Program of Core C has established a unique repository of tissues and muscle cells from FSHD patients and families, a gene expression database for biomarker discovery, and innovative animal models for FSHD therapeutic development. Consultants for Core C include:
Stephen D. Hauschka, Ph.D., Professor of Biochemistry?University of Washington, Seattle, Washington.
Terence A. Partridge Ph.D., FMedSci, [CNMC DC Wellstone MD CRC] Researcher, Center for Genetic Medicine Research, Children's National Medical Center, Washington D.C.
Steven Moore, M.D., Ph.D. [Iowa Wellstone MD CRC] Department of Pathology, University of Iowa College of Medicine, and, Co-Director of the University of Iowa Wellstone MD CRC?University of Iowa, Iowa City, Iowa
The Wellstone MD CRC Projects 1-4 have extensive support from academic collaborators who are experts in FSHD research, translational research and clinical trials. Our Wellstone MD CRC has twice hosted the FSHD International Workshop and received strong support from the entire FSHD and muscular dystrophy research and clinical community worldwide. Our Wellstone MD CRC also hosted the 2012 Wellstone Network meeting, bringing together the six Wellstone Centers and other NIH-funded muscular dystrophy programs for discussion and data sharing towards development of new lines of therapeutics for muscular dystrophy. Finally, a Center Advisory Committee of leading experts in muscular dystrophy research and therapeutic development meets annually with our Center PIs and fellows to give critical feedback on research progress and recommend future directions (advisory committee).
Wellstone MD CRC has collaborations with industry, institutes, universities and patient organizations to support the Wellstone repository and research projects for development of FSHD therapeutics and clinical trials. The Center currently has development projects with Amgen and Genzyme/Sanofi to commercialize therapies for FSHD and muscular dystrophy; the Rutgers University Cell and DNA Repository, for storage and preservation of our cell repository; and Harvard University Genetic Modification Facility (HUGMF) for mouse housing/transgenic mouse models. Our research has leveraged significant research funding from foundations, including the FSHD Society, Thoracic Foundation and MDA, and the NIH to fund new FSHD research initiatives and support career development of promising FSHD researchers.
The FSH Society [FSHD Volunteer Health Agency/FSHD Patient Organization] is key partner, fully integrated into the research and patient recruitment activities of our Center. The FSH Society is a leading force in patient education and advocacy, bringing together FSHD researchers and patients for information sharing, personal and professional exchanges and interactions that will support research leading to FSHD clinical trials. Daniel Perez serves as Director of the Office of Patient Communication and Liaison (OPCL).